InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Fuchs Henry J, Director. Officer active across 3 companies, notably Mirati Therapeutics, Inc.. Aggregated, 14 reports have been logged. Breakdown: 0 buy · 2 sells. Total volume traded: €3.8m. History available since 14 January 2022. The latest transaction was disclosed on 30 April 2024 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Fuchs Henry J
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
300 shares@ US$68.6460.5% of flowCommon StockSEC:0001048477-24-000141:0
18,240 shares0Common StockSEC:0001048477-24-000042:0
35,341 shares@ US$85.181473.0% of flowCommon StockSEC:0001048477-24-000034:0
30,640 shares0Common StockSEC:0001048477-24-000020:0
317 shares@ US$66.8780.5% of flowCommon StockSEC:0001048477-23-000049:0
12,000 shares@ US$90.425926.0% of flowCommon StockSEC:0001048477-23-000037:0
16,840 shares0Common StockSEC:0001567619-23-005295:0
36,440 shares0Common StockSEC:0001209191-23-014606:0
4,444 shares0Common StockSEC:0001214659-23-001040:0
38,790 shares0Common StockSEC:0001567619-22-007187:0
12,840 shares0Common StockSEC:0001567619-22-006718:0
6,000 shares@ US$20.54100.0% of flowCommon StockSEC:0001214659-22-002681:0
2,546 shares0Common StockSEC:0001214659-22-000847:0
284 sharesCommon StockSEC:0001209191-16-088611:0
14 of 14 declarations
About Fuchs Henry J
Henry J. Fuchs is a Director and President of Worldwide R&D at Mirati Therapeutics, Inc. and BIOMARIN PHARMACEUTICAL INC. In his roles, he oversees research and development initiatives and contributes to the overall strategy of the companies. With a strong background in the pharmaceutical sector, he is committed to promoting innovation and improving patient outcomes.
